
4721
237
CMV IE
Promoter/activator
HindIII
Kanamycin
resistance
920
3798
CMV IE
5' UT
pVR1012
(4915 bp)
1863
3497
PstI
SalI
PmlI
BclI
EcoRV
NotI
XbaI
BamHI
BglII
1935
BGH Term
2482

Figure No. 1


6610
237
CMV IE
Promoter/activator
920
CMV IE
5' UT
1863
PstI
SalI
HindIII
BclI
KpnI
SacII
BamHI
BglII
BGH Term
4371
5386
HindIII
Kanamycin
resistance
pPB179
(6804 bp)
FeLV
env A

Figure No. 2

```
   1 ATGGAAGGTCCAACGCACCCAAAACCCTCTAAAGATAAGACTTTCTCGTGGGACCTAATGATT
   1 MetGluGlyProThrHisProLysProSerLysAspLysThrPheSerTrpAspLeuMetIle

  64 CTGGTGGGGGTCTTACTAAGACTGGACGTGGGAATGGCCAATCCTAGTCCGCACCAAATATAT
  22 LeuValGlyValLeuLeuArgLeuAspValGlyMetAlaAsnProSerProHisGlnIleTyr

 127 AATGTAACTTGGACAATAACCAACCTTGTAACTGGAACAAAGGCTAATGCCACCTCCATGTTG
  43 AsnValThrTrpThrIleThrAsnLeuValThrGlyThrLysAlaAsnAlaThrSerMetLeu

 190 GGAACCCTGACAGACGCCTTCCCTACCATGTATTTTGACTTATGTGATATAATAGGAAATACA
  64 GlyThrLeuThrAspAlaPheProThrMetTyrPheAspLeuCysAspIleIleGlyAsnThr

 253 TGGAACCCTTCAGATCAAGAACCATTCCCAGGGTATGGATGTGATCAGCCTATGAGGAGGTGG
  85 TrpAsnProSerAspGlnGluProPheProGlyTyrGlyCysAspGlnProMetArgArgTrp

 316 CGACAGAGAAACACACCCTTTTATGTCTGTCCAGGACATGCCAACCGGAAGCAATGTGGGGGG
 106 ArgGlnArgAsnThrProPheTyrValCysProGlyHisAlaAsnArgLysGlnCysGlyGly

 379 CCACAGGATGGGTTCTGCGCTGTATGGGGTTGCGAGACCACCGGGGAAACCTATTGGAGACCC
 127 ProGlnAspGlyPheCysAlaValTrpGlyCysGluThrThrGlyGluThrTyrTrpArgPro

 442 ACCTCCTCATGGGACTACATCACAGTAAAAAAAGGGGTTACTCAGGGAATATATCAATGTAGT
 148 ThrSerSerTrpAspTyrIleThrValLysLysGlyValThrGlnGlyIleTyrGlnCysSer

 505 GGAGGTGGTTGGTGTGGGCCCTGTTACGATAAAGCTGTTCACTCCTCGACAACGGGAGCTAGT
 169 GlyGlyGlyTrpCysGlyProCysTyrAspLysAlaValHisSerSerThrThrGlyAlaSer

 568 GAAGGGGGCCGGTGCAACCCCTTGATCTTGCAATTTACCCAAAAGGGAAGACAAACATCTTGG
 190 GluGlyGlyArgCysAsnProLeuIleLeuGlnPheThrGlnLysGlyArgGlnThrSerTrp

 631 GATGGACCTAAGTCATGGGGGCTACGACTATACCGTTCAGGATATGACCCTATAGCCCTGTTC
 211 AspGlyProLysSerTrpGlyLeuArgLeuTyrArgSerGlyTyrAspProIleAlaLeuPhe

 694 TCGGTATCCCGGCAAGTAATGACCATTACGCCGCCTCAGGCCATGGGACCAAATCTAGTCCTG
 232 SerValSerArgGlnValMetThrIleThrProProGlnAlaMetGlyProAsnLeuValLeu

 757 CCTGATCAAAAACCCCCATCCAGGCAATCTCAAATAGAGTCCCGAGTAACACCTCACCATTCC
 253 ProAspGlnLysProProSerArgGlnSerGlnIleGluSerArgValThrProHisHisSer

 820 CAAGGCAACGGAGGCACCCCAGGTGTAACTCTTGTTAATGCCTCCATTGCCCCTCTACGTACC
 274 GlnGlyAsnGlyGlyThrProGlyValThrLeuValAsnAlaSerIleAlaProLeuArgThr

 883 CCTGTCACCCCCGCAAGTCCCAAACGTATAGGGACCGGAAATAGGTTAATAAATTTAGTGCAA
 295 ProValThrProAlaSerProLysArgIleGlyThrGlyAsnArgLeuIleAsnLeuValGln

 946 GGGACATACCTAGCCTTAAATGCCACCGACCCCAACAAAACTAAAGACTGTTGGCTCTGCCTG
 316 GlyThrTyrLeuAlaLeuAsnAlaThrAspProAsnLysThrLysAspCysTrpLeuCysLeu

1009 GTTTCTCGACCACCTTATTACGAAGGGATTGCAATCTTAGGTAACTACAGCAACCAAACAAAC
 337 ValSerArgProProTyrTyrGluGlyIleAlaIleLeuGlyAsnTyrSerAsnGlnThrAsn

1072 CCCTCCCCATCCTGCCTATCTACTCCGCAACATAAGCTAACTATATCTGAGGTGTCAGGGCAA
 358 ProSerProSerCysLeuSerThrProGlnHisLysLeuThrIleSerGluValSerGlyGln

1135 GGACTGTGCATAGGGACTGTTCCTAAGACCCACCAGGCTTTGTGCAATAAGACACAACAGGGA
 379 GlyLeuCysIleGlyThrValProLysThrHisGlnAlaLeuCysAsnLysThrGlnGlnGly

1198 CATACAGGGGCTCACTATCTAGCCGCCCCCAATGGCACCTATTGGGCCTGTAACACTGGACTC
 400 HisThrGlyAlaHisTyrLeuAlaAlaProAsnGlyThrTyrTrpAlaCysAsnThrGlyLeu
```

FORM PCT/RO/134 (JULY 1992)

Figure No. 3

```
1261 ACCCCATGCATTTCCATGGCAGTGCTCAATTGGACCTCTGATTTTTGTGTCTTAATCGAATTA
 421▶ThrProCysIleSerMetAlaValLeuAsnTrpThrSerAspPheCysValLeuIleGluLeu

1324 TGGCCCAGAGTGACCTACCATCAACCCGAATACATTTACACACATTTCGACAAAGCTGTCAGG
 442▶TrpProArgValThrTyrHisGlnProGluTyrIleTyrThrHisPheAspLysAlaValArg

1387 TTCCGAAGAGAACCAATATCACTAACCGTTGCCCTTATAATGGGAGGACTCACTGTAGGGGGC
 463▶PheArgArgGluProIleSerLeuThrValAlaLeuIleMetGlyGlyLeuThrValGlyGly

1450 ATAGCCGCGGGGGTCGGAACAGGGACTAAAGCCCTCCTTGAAACAGCCCAGTTCAGACAACTA
 484▶IleAlaAlaGlyValGlyThrGlyThrLysAlaLeuLeuGluThrAlaGlnPheArgGlnLeu

1513 CAAATGGCTATGCACGCAGACATCCAGGCCCTAGAAGAGTCAATTAGTGCCTTAGAAAAATCC
 505▶GlnMetAlaMetHisAlaAspIleGlnAlaLeuGluGluSerIleSerAlaLeuGluLysSer

1576 CTGACCTCCCTCTCCGAGGTAGTCTTACAAAATAGACGGGGCCTAGATATTCTGTTCTTACAA
 526▶LeuThrSerLeuSerGluValValLeuGlnAsnArgArgGlyLeuAspIleLeuPheLeuGln

1639 AAGGGAGGGCTCTGTGCCGCCTTAAAGGAAGAATGCTGCTTCTATGCAGATCACACCGGACTC
 547▶LysGlyGlyLeuCysAlaAlaLeuLysGluGluCysCysPheTyrAlaAspHisThrGlyLeu

1702 GTCAGAGACAATATGGCTAAATTAAGAGAAAGACTGAAACAGCGACAACAACTGTTTGACTCC
 568▶ValArgAspAsnMetAlaLysLeuArgGluArgLeuLysGlnArgGlnGlnLeuPheAspSer

1765 CAACAGGGATGGTTTGAAGGATGGTTCAACAAGTCCCCCTGGTTTACAACCCTAATTTCCTCC
 589▶GlnGlnGlyTrpPheGluGlyTrpPheAsnLysSerProTrpPheThrThrLeuIleSerSer

1828 ATTATAGGCCCCTTACTAATCCTACTCCTAATTCTCCTCTTCGGCCCATGCATCCTTAACCGA
 610▶IleIleGlyProLeuLeuIleLeuLeuLeuIleLeuLeuPheGlyProCysIleLeuAsnArg

1891 TTAGTGCAATTCGTAAAAGACAGAATATCTGTGGTACAAGCCTTAATTTTAACCCAACAGTAC
 631▶LeuValGlnPheValLysAspArgIleSerValValGlnAlaLeuIleLeuThrGlnGlnTyr

1954 CAACAGATACAGCAATATGATCCGGACCGACCATGA
 652▶GlnGlnIleGlnGlnTyrAspProAspArgPro•••
```

Figure No. 3 (continuation and end)


6669
237
CMV IE
Promoter/activator
920
CMV IE
5' UT
1863
PstI
SalI
AcyI
BclI
ApaI
NcoI
BclI
NsiI
NcoI
SacII
NsiI
BamHI
BglII
3883
BGH Term
4430
FeLV
env B
5445
5746
HindIII
Kanamycin
resistance
pPB180
(6863 bp)

Figure No. 4

```
   1 ATGTCTGGAGCCTCTAGTGGGACAGCCATTGGGGCTCATCTGTTTGGGGTCTCACCTGAATAC
   1 MetSerGlyAlaSerSerGlyThrAlaIleGlyAlaHisLeuPheGlyValSerProGluTyr

  64 AGGGTGTTGATCGGAGACGAGGGAGCCGGACCCTCAAGGTCTCTTTCTGAGGTTTCATTTTCG
  22 ArgValLeuIleGlyAspGluGlyAlaGlyProSerArgSerLeuSerGluValSerPheSer

 127 GTTTGGTACCAAAGACGCGCGGCACGTCTTGTCATTTTTTGTCTGGTTGCGTCTTTTCTTGTC
  43 ValTrpTyrGlnArgArgAlaAlaArgLeuValIlePheCysLeuValAlaSerPheLeuVal

 190 CCTTGTCTAACCTTTTTAATTGCAGAAACCGTCATGGGCCAAACTATAACTACCCCCTTAAGC
  64 ProCysLeuThrPheLeuIleAlaGluThrValMetGlyGlnThrIleThrThrProLeuSer

 253 CTCACCCTTGATCACTGGTCTGAAGTCCGGGCACGAGCCCATAATCAAGGTGTCGAGGTCCGG
  85 LeuThrLeuAspHisTrpSerGluValArgAlaArgAlaHisAsnGlnGlyValGluValArg

 316 AAAAAGAAATGGATTACCTTATGTGAGGCCGAATGGGTGATGATGAATGTGGGCTGGCCCCGA
 106 LysLysLysTrpIleThrLeuCysGluAlaGluTrpValMetMetAsnValGlyTrpProArg

 379 GAAGGAACTTTTTCTCTTGATAGCATTTCCCAGGTTGAAAAGAAGATCTTCGCCCCGGGACCA
 127 GluGlyThrPheSerLeuAspSerIleSerGlnValGluLysLysIlePheAlaProGlyPro

 442 TATGGACACCCCGACCAAGTTCCTTACATTACTACATGGAGATCCTTAGCCACAGACCCCCCT
 148 TyrGlyHisProAspGlnValProTyrIleThrThrTrpArgSerLeuAlaThrAspProPro

 505 TCGTGGGTTCGTCCGTTCCTACCCCCTCCCAAACCTCCCACACCCCTCCCTCAACCTCTTTCG
 169 SerTrpValArgProPheLeuProProProLysProProThrProLeuProGlnProLeuSer

 568 CCGCAGCCCTCCGCCCCTCTTACCTCTTCCCTCTACCCCGTTCTCCCCAAGCCAGACCCCCCC
 190 ProGlnProSerAlaProLeuThrSerSerLeuTyrProValLeuProLysProAspProPro

 631 AAACCGCCTGTGTTACCGCCTGATCCTTCTTCCCCTTTAATTGATCTCTTAACAGAAGAGCCA
 211 LysProProValLeuProProAspProSerSerProLeuIleAspLeuLeuThrGluGluPro

 694 CCTCCCTATCCGGGGGGTCACGGGCCACCGCCATCAGGTCCTAGGACCCCAACCGCTTCCCCG
 232 ProProTyrProGlyGlyHisGlyProProProSerGlyProArgThrProThrAlaSerPro

 757 ATTGCAAGCCGGCTAAGGGAACGACGAGAAAACCCTGCTGAAGAATCGCAAGCCCTCCCCTTG
 253 IleAlaSerArgLeuArgGluArgArgGluAsnProAlaGluGluSerGlnAlaLeuProLeu

 820 AGGGAAGGCCCCAACAACCGACCCCAGTATTGGCCATTCTCAGCTTCAGACTTGTATAACTGG
 274 ArgGluGlyProAsnAsnArgProGlnTyrTrpProPheSerAlaSerAspLeuTyrAsnTrp

 883 AAGTCGCATAACCCCCCTTTCTCCCAAGATCCAGTGGCCCTAACTAACCTAATTGAGTCCATT
 295 LysSerHisAsnProProPheSerGlnAspProValAlaLeuThrAsnLeuIleGluSerIle

 946 TTAGTGACGCATCAACCAACCTGGGACGACTGCCAGCAGCTCTTGCAGGCACTCCTGACAGGC
 316 LeuValThrHisGlnProThrTrpAspAspCysGlnGlnLeuLeuGlnAlaLeuLeuThrGly

1009 GAAGAAAGGCAAAGGGTCCTTCTTGAGGCCCGAAAGCAGGTTCCAGGCGAGGACGGACGGCCA
 337 GluGluArgGlnArgValLeuLeuGluAlaArgLysGlnValProGlyGluAspGlyArgPro

1072 ACCCAACTACCCAATGTCATTGACGAGACTTTCCCCTTGACCCGTCCCAACTGGGATTTTGCT
 358 ThrGlnLeuProAsnValIleAspGluThrPheProLeuThrArgProAsnTrpAspPheAla

1135 ACGCCGGCAGGTAGGGAGCACCTACGCCTTTATCGCCAGTTGCTATTAGCGGGTCTCCGCGGG
 379 ThrProAlaGlyArgGluHisLeuArgLeuTyrArgGlnLeuLeuLeuAlaGlyLeuArgGly
```

Figure No. 5

Page 8 of the Patent

```
1198 GCTGCAAGACGCCCCACTAATTTGGCACAGGTAAAGCAGGTTGTACAAGGGAAAGAGGAAACG
 400▶AlaAlaArgArgProThrAsnLeuAlaGlnValLysGlnValValGlnGlyLysGluGluThr

1261 CCAGCAGCATTTTTAGAAAGATTAAAAGAGGCTTATAGAATGTACACTCCCTATGACCCTGAG
 421▶ProAlaAlaPheLeuGluArgLeuLysGluAlaTyrArgMetTyrThrProTyrAspProGlu

1324 GACCCAGGGCAAGCGGCTAGTGTTATCCTATCCTTTATATACCAGTCTAGCCCAGATATAAGA
 442▶AspProGlyGlnAlaAlaSerValIleLeuSerPheIleTyrGlnSerSerProAspIleArg

1387 AATAAGTTACAAAGGCTAGAAGGCCTACAAGGGTTCACCCTATCTGATCTGCTAAAAGAGGCA
 463▶AsnLysLeuGlnArgLeuGluGlyLeuGlnGlyPheThrLeuSerAspLeuLeuLysGluAla

1450 GAAAAGATATACAACAAAAGGGAGACCCCAGAGGAAAGGGAAGAAAGATTATGGCAGCGACAG
 484▶GluLysIleTyrAsnLysArgGluThrProGluGluArgGluGluArgLeuTrpGlnArgGln

1513 GAAGAAAGAGATAAAAAGCGCCACAAGGAGATGACTAAAGTTCTGGCCACAGTAGTTGCTCAG
 505▶GluGluArgAspLysLysArgHisLysGluMetThrLysValLeuAlaThrValValAlaGln

1576 AATAGAGATAAGGATAGAGAAGAAAGTAAACTGGGGGATCAAAGGAAAATACCTCTGGGGAAA
 526▶AsnArgAspLysAspArgGluGluSerLysLeuGlyAspGlnArgLysIleProLeuGlyLys

1639 GACCAGTGTGCCTATTGCAAGGAAAAGGGGCATTGGGTTCGCGATTGCCCCAAACGACCCAGG
 547▶AspGlnCysAlaTyrCysLysGluLysGlyHisTrpValArgAspCysProLysArgProArg

1702 AAGAAACCCGCCAACTCCACTCTCCTCAACTTAGGAGATTAGGAGAGTCAGGGCCAGGACCCC
 568▶LysLysProAlaAsnSerThrLeuLeuAsnLeuGlyAsp•••
                                    1▶GluIleArgArgValArgAlaArgThrPr

1765 CCCCCCTGAGCCCAGGATAACCTTAAAAATAGGGGGGCAACCGGTGACTTTTCTGGTGGACAC
   10▶oProProGluProArgIleThrLeuLysIleGlyGlyGlnProValThrPheLeuValAspTh

1828 GGGAGCCCAGCACTCAGTACTGACTCGACCAGATGGACCTCTCAGTGACCGCACAGCCCTGGT
   31▶rGlyAlaGlnHisSerValLeuThrArgProAspGlyProLeuSerAspArgThrAlaLeuVa

1891 GCAAGGAGCCACGGGAAGCAAAAACTACCGGTGGACCACCGACAGGAGGGTACAACTGGCAAC
   52▶lGlnGlyAlaThrGlySerLysAsnTyrArgTrpThrThrAspArgArgValGlnLeuAlaTh

1954 CGGTAAGGTGACTCATTCTTTTTTATATGTACCTGAATGTCCCTACCCGTTATTAGGGAGAGA
   73▶rGlyLysValThrHisSerPheLeuTyrValProGluCysProTyrProLeuLeuGlyArgAs

2017 CCTATTAACTAAACTTAAGGCCCAAATCCATTTTACCGGAGAAGGGGCTAATGTTGTTGGGCC
   94▶pLeuLeuThrLysLeuLysAlaGlnIleHisPheThrGlyGluGlyAlaAsnValValGlyPr

2080 CAGGGGTTTACCCCTACAAGTCCTTACTTTACAATTAGAAGAGGAGTATCGGCTATTTGAGCC
  115▶oArgGlyLeuProLeuGlnValLeuThrLeuGlnLeuGluGluGluTyrArgLeuPheGluPr

2143 AGAAAGTACACAAAAACAGGAGATGGACACTTGGCTTAAAAACTTTCCCCAGGCGTGGGCAGA
  136▶oGluSerThrGlnLysGlnGluMetAspThrTrpLeuLysAsnPheProGlnAlaTrpAlaGl
```

Figure No. 5 (continuation)

2206 AACAGGAGGTATGGGAATGGCTCATTGTCAAGCCCCCGTTCTCATTCAACTTAAGGCTACTGC

157▶uThrGlyGlyMetGlyMetAlaHisCysGlnAlaProValLeuIleGlnLeuLysAlaThrAl

2269 CACTCCAATCTCCATCCGACAGTATCCTATGCCCCATGAAGCGTACCAGGGAATTAAGCCTCA

178▶aThrProIleSerIleArgGlnTyrProMetProHisGluAlaTyrGlnGlyIleLysProHi

2332 TATAAGAAGAATGCTAGATCAAGGCATCCTCAAGCCCTGCCAGTCCCCATGGAATACACCCTT

199▶sIleArgArgMetLeuAspGlnGlyIleLeuLysProCysGlnSerProTrpAsnThrProLe

2395 ATTACCTGTTAAGAAGCCAGGGACCGAGGATTACAGACCAGTGCAGGACTTAAGAGAAGTAAA

220▶uLeuProValLysLysProGlyThrGluAspTyrArgProValGlnAspLeuArgGluValAs

2458 CAAAAGAGTAGAAGACATCCATCCTACTGTGCCAAATCCATATAACCTCCTTAGCACCCTCCC

241▶nLysArgValGluAspIleHisProThrValProAsnProTyrAsnLeuLeuSerThrLeuPr

2521 GCCGTCTCACCCTTGGTACACTGTCCTAGATTTAAAGGACGCTTTTTTCTGCCTGCGACTACA

262▶oProSerHisProTrpTyrThrValLeuAspLeuLysAspAlaPhePheCysLeuArgLeuHi

2584 CTCTGAGAGTCAGTTACTTTTTGCATTTGAATGGAGAGATCCAGAAATAGGACTGTCAGGGCA

283▶sSerGluSerGlnLeuLeuPheAlaPheGluTrpArgAspProGluIleGlyLeuSerGlyGl

2647 ACTAACCTGGACACGCCTTCCTCAGGGGTTCAAGAATAGCCCCACCCTATTTGATGAGGCCCT

304▶nLeuThrTrpThrArgLeuProGlnGlyPheLysAsnSerProThrLeuPheAspGluAlaLe

2710 GCACTCAGACCTGGCCGATTTCAGGGTAAGGTACCCGGCTCTAGTCCTCCTACAATATGTAGA

325▶uHisSerAspLeuAlaAspPheArgValArgTyrProAlaLeuValLeuLeuGlnTyrValAs

2773 TGACCTCTTGCTGGCTGCGGCAACCAGGACTGAATGCCTGGAAGGGACTAAGGCACTCCTTGA

346▶pAspLeuLeuLeuAlaAlaAlaThrArgThrGluCysLeuGluGlyThrLysAlaLeuLeuGl

2836 GACTTTGGGCAATAAGGGGTACCGAGCCTCTGGAAAGAAGGCCCAAATTTGCCTGCAAGAAGT

367▶uThrLeuGlyAsnLysGlyTyrArgAlaSerGlyLysLysAlaGlnIleCysLeuGlnGluVa

2899 CACATACCTGGGGTACTCTTTAAAAGATGGCCAAAGGTGGCTTACCAAAGCTCGGAAAGAAGC

388▶lThrTyrLeuGlyTyrSerLeuLysAspGlyGlnArgTrpLeuThrLysAlaArgLysGluAl

2962 CATCCTATCCATCCCTGTGCCTAAAAACCCACGACAAGTGAGAGAGTTCCTTGGAACTGCAG

409▶aIleLeuSerIleProValProLysAsnProArgGlnValArgGluPheLeuGlyThrAla

Figure No. 5 (continuation and end)


7714
237
HindIII
CMV IE
Promoter/activator
920
Kanamycin.
resistance
CMV IE
5' UT
6490
1863
PstI
SalI
pPB181
(7908 bp)
BclI
BglII
SmaI
NdeI
FeLV
gag-pol
5475
BGH Term
4928
BglII
PstI
BamHI
NcoI
SacII
StuI

Figure No. 6


6470
237
CMV IE
Promoter/activator
HindIII
920
Kanamycin
resistance
5547
CMV IE
5' UT
5246
pAB009
(6664 bp)
1863
PstI
SalI
PmlI
BclI
EcoRV
NotI
XbaI
PstI
FPV
VP2
BglII
4231
BGH Term
3684
BglII
BamHI
MfeI
EcoRV

Figure No. 7


9088
237
SpeI
CMV IE
Promoter/activator
920
CMV IE
5' UT
1863
PstI
SalI
PmlI
BclI
EcoRV
NotI
EcoRI
SspI
HindIII
FIPV
S*
HindIII
SpeI
XbaI
NotI
BamHI
BglII
6302
BGH
Term
6849
7864
8165
HindIII
Kanamycin
resistance
pAB053
(9282 bp)

Figure No. 8


5474
237
CMV IE
Promoter/activator
HindIII
920
Kanamycin
resistance
4551
CMV IE
5' UT
pAB052
(5668 bp)
4250
1863
FIPV
M
PstI
SalI
3235
BGH Term
BamHI
2688
BglII

Figure No. 9


5817
237
CMV IE
Promoter/activator
HindIII
920
Kanamycin
resistance
CMV IE
5' UT
4593
pAB056
(6011 bp)
HindII
1863
PstI
SalI
HindII
HindII
FIV
N
XbaI
BglII
XbaI
BglII
PstI
3578
BGH Term
BclI
BamHI
3026
BglII

Figure No. 10


7526
237
HindIII
CMV IE
Promoter/activator
920
6603
Kanamycin
resistance
6302
CMV IE
5' UT
1863
pAB028
(7720 bp)
PstI
5287
BGH Term
FHV-1
gB
BglII
BamHI
BglII
4740
BglII
BamHI
XbaI
XbaI
NotI
BclI

Figure No. 11


5788
237
CMV IE
Promoter/activator
HindIII
920
Kanamycin
resistance
4865
CMV IE
5' UT
4564
pAB029
(5982 bp)
1863
PstI
FHV-1
gD
BamHI
EcoRV
3549
BGH Term
Xbal
3002 BglII

Figure No. 12


6698
237
CMV IE
Promoter/activator
HindIII
920
5775
Kanamycin
resistance
5474
CMV IE
5' UT
pAB010
(6892 bp)
1863
PstI
SalI
PstI
FCV
capsid gene
XbaI
4459
BGH Term
3912 BglII
BamHI

Figure No. 13


7244
237
HindIII
CMV IE
Promoter/activator
920
6321
Kanamycin
resistance
6020
CMV IE
5' UT
pAB030
(7436 bp)
1863
PstI
BglII
5005
BGH Term
FIV
Env
BclI
4458
BglII
DraI
BamHI

Figure No. 14


HindIII
9296
237
CMV IE
Promoter/activator
920
CMV IE
5' UT
1863
PstI
SalI
PstI
PstI
PstI
PstI
EcoRV
BamHI
XbaI
BamHI
EcoRV
6510
BglII
BGH Term
7057
8072
8373
Kanamycin
resistance
pAB083
(9490 bp)
FIV
Gag-Pol

Figure No. 15


6243
237
CMV IE
Promoter/activator
HindIII
920
5320
Kanamycin
resistance
CMV IE
5' UT
5019
pAB041
(6437 bp)
1863
PstI
RABIES
G
4004
BGH Term
3457
BamHI
BglII

Figure No. 16